Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNO Withdrawal Study in PAH Patients on LTOT
NCT03602781Phase 3Withdrawn
- Sponsor
- Bellerophon Therapeutics
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Placebo Withdrawal with iNO Maintenance (2 arms). Primary endpoint: Time to clinical worsening during iNO withdrawal at 8 weeks. Planned start Aug 2018; status: withdrawn.
02
Drugs
nitric oxide
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03602781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602781.